Clinical trials: Neoplasia Prostate
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
- Trial name
- SCOUT (NCT07011342)
- Testing
- 18F-rhPSMA-7.3
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Hackensack Meridian Health
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Metastatic Castration-resistant Prostate Cancer
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
- Trial name
- NCT05558956
- Testing
- illuccix 68Ga-PSMA-11 Total Body PET-CT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- BAMF Health
Metastatic Hormone-sensitive Prostate Cancer
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to systemically treat the disease with androgen deprivation therapy (ADT).
- Trial name
- NCT03879122
- Testing
- Ipilimumab 5 MG/ML, Nivolumab 10 MG/ML, Docetaxel
- Where
- 30 sites in Spain
- Volunteers
- 135 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Cancer
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain.
- Trial name
- COMART (NCT00590213)
- Testing
- Casodex 150mg, Radiotherapy, Haematology
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Prostate Cancer
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This is a prospective, open-label, single-center, dose-escalation study using a standard 3+3 design to assess the safety, tolerability, biodistribution/dosimetry and preliminary efficacy of the albumin-binding PSMA radioligand…
- Trial name
- 161Tb-LNC1011 (NCT07381582)
- Testing
- 161Tb-LNC1011
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Prostate Cancer
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers
AdOTAC is a pilot study, open, prospective, single-center, one-arm. The 200 patients will be included. Patient is included at Day 0.
- Trial name
- AdOTAC (NCT06435546)
- Testing
- Blood samples, Adherence to anti-cancer therapies questionnaires
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut de Cancérologie de Lorraine
Prostate Cancer
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00430183
- Testing
- docetaxel, LHRH agonist, surgery
- Where
- 226 sites in United States, Canada
- Volunteers
- 788 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Gynecologic Cancer
Implementation of a Multimodal Prehabilitation Program in Robotic Oncological Surgery
Current literature on prehabilitation is broad and heterogenous. Ploussard et al initiated a multimodal one-day prehabilitation program in patients before robotic radical prostatectomy involving urology nurses, anaesthetic…
- Trial name
- NCT05671094
- Testing
- Prehabilitation
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Jessa Hospital
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
This early phase I is to find out how common vitamin D insufficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the body (localized) or has spread to other places in…
- Conditions
- Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
- Trial name
- NCT05045066
- Testing
- Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
RATIONALE: Genistein may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of genistein in treating patients with localized prostate…
- Trial name
- NCT00058266
- Testing
- genistein, conventional surgery
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with…
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
- Trial name
- DIVINE (NCT06378866)
- Testing
- Abiraterone, Apalutamide, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 532 people
- Sponsor
- Mayo Clinic
High-risk Prostate Cancer, PSMA PET
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
This prospective, multicenter study aims to evaluate the clinical utility of serial PSMA PET for therapy monitoring in patients with newly diagnosed clinically significant prostate cancer.
- Conditions
- High-risk Prostate Cancer, PSMA PET, Treatment Response, Therapy Monitoring
- Trial name
- PSMA-TM (NCT07553780)
- Where
- 9 sites in China
- Volunteers
- 110 people
- Sponsor
- Xijing Hospital
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as…
- Trial name
- NCT07226986
- Testing
- AMO959, AAA617, Enzalutamide
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
This clinical trial is for men with advanced prostate cancer that may have spread to other parts of the body. Currently, once prostate cancer cells have spread from the prostate to other organs it is not treatable by surgery.
- Trial name
- NCT02552394
- Testing
- huJ591
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Radical prostatectomy may be an effective treatment for locally advanced prostate cancer. PURPOSE: Phase II trial to study the effectiveness of radical prostatectomy in treating patients who have locally advanced…
- Trial name
- NCT00027794
- Testing
- conventional surgery
- Where
- 5 sites in Belgium, Italy and 1 more
- Volunteers
- 40 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer
Short-term Efficacy of Transperineal Laser Ablation (TPLA) with Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an interventional pilot study.
- Trial name
- NCT04045756
- Testing
- Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Rome Tor Vergata
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.